Literature DB >> 1426003

Vasodilatory effects of adenosine A2 receptor agonists CGS 21680 and CGS 22492 in human vasculature.

S R Makujina1, M H Sabouni, S Bhatia, F L Douglas, S J Mustafa.   

Abstract

The vasodilatory effects of the adenosine analogs, 5'-N-ethylcarboxamidoadenosine (NECA), 2-[p-(2-carboxyethyl)phenethyl amino]-5'-N-ethylcarboxamidoadenosine (CGS 21680) and 2-[(2-cyclohexylethyl)amino]adenosine (CGS 22492) in human coronary, internal mammary artery and saphenous vein were examined in vitro. All produced concentration-dependent relaxations in arterial as well as venous rings contracted with 35 mM KCl. The concentration-response curves for NECA and CGS 21680 were parallel in the coronary. The adenosine A2 receptor antagonist, 9-chloro-2-(2-furyl)[1,2,4]triazolo[1,5-c]quinazolin-5-amine (CGS 15943A) significantly attenuated the relaxing response to the adenosine analogs in coronary artery. Although NECA and CGS 22492 were equally as effective at the highest concentration administered (both achieving approximately 70% relaxation at 10(-4) M) NECA (EC50 = 1.25 +/- 0.11 microM) induced greater vasodilation at lower concentrations than CGS 22492 (EC50 = 11.27 +/- 1.53 microM). CGS 21680 was the least potent of the agents tested achieving only 44% relaxation at 10(-4) M (EC50 = 4.71 +/- 0.46 microM). Coronary artery appeared to be more responsive than internal mammary artery or saphenous vein which displayed only marginal relaxation to these agents.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1426003     DOI: 10.1016/0014-2999(92)90708-c

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology.

Authors:  S Jamal Mustafa; R Ray Morrison; Bunyen Teng; Amir Pelleg
Journal:  Handb Exp Pharmacol       Date:  2009

2.  Evidence for the presence of A(1) adenosine receptors in the aorta of spontaneously hypertensive rats.

Authors:  M Fahim; S J Mustafa
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

Review 3.  CD39 in the development and progression of pulmonary arterial hypertension.

Authors:  Abbey Willcox; Natasha Ting Lee; Harshal H Nandurkar; Maithili Sashindranath
Journal:  Purinergic Signal       Date:  2022-08-10       Impact factor: 3.950

4.  Vascular actions of purines in the foetal circulation of the human placenta.

Authors:  M A Read; A L Boura; W A Walters
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

5.  Effects of selective A1 and A2 adenosine receptor agonists on cardiovascular tissues.

Authors:  A Conti; A Monopoli; M Gamba; P A Borea; E Ongini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

6.  Effects of the new A2 adenosine receptor antagonist 8FB-PTP, an 8 substituted pyrazolo-triazolo-pyrimidine, on in vitro functional models.

Authors:  S Dionisotti; A Conti; D Sandoli; C Zocchi; F Gatta; E Ongini
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

7.  Phenotyping of Mice with Heart Specific Overexpression of A2A-Adenosine Receptors: Evidence for Cardioprotective Effects of A2A-Adenosine Receptors.

Authors:  Peter Boknik; Katharina Drzewiecki; John Eskandar; Ulrich Gergs; Stephanie Grote-Wessels; Larissa Fabritz; Paulus Kirchhof; Frank U Müller; Frank Stümpel; Wilhelm Schmitz; Norbert Zimmermann; Uwe Kirchhefer; Joachim Neumann
Journal:  Front Pharmacol       Date:  2018-01-22       Impact factor: 5.810

8.  Non-Invasive Assessment of Locally Overexpressed Human Adenosine 2A Receptors in the Heart of Transgenic Mice.

Authors:  Daniel Gündel; Thu Hang Lai; Sladjana Dukic-Stefanovic; Rodrigo Teodoro; Winnie Deuther-Conrad; Magali Toussaint; Klaus Kopka; Rareş-Petru Moldovan; Peter Boknik; Britt Hofmann; Ulrich Gergs; Joachim Neumann; Peter Brust
Journal:  Int J Mol Sci       Date:  2022-01-18       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.